Latigo Biotherapeutics, Inc. press release (LTGO): Q3 GAAP EPS of -$0.55 beats by $0.12. Cash and cash equivalents of $401 million expected to fund operations i
CryptoAlerta — análise de criptomoedas e mercado em tempo real